SPOTLIGHT -
Phase III Trial of Lenvatinib, Pembrolizumab, and Belzutifan or Quavonlimab in Frontline Advanced RCC
The panel continues their discussion of investigational triplet therapies in frontline RCC treatment.
COSMIC-313 Trial of Cabozantinib, Nivolumab and Ipilimumab in Frontline Advanced RCC
The doctors review data from the COSMIC-313 trial investigating a frontline triplet therapy for advanced RCC.
Approaches to Dosing TKIs in Patients with Advanced RCC
Best approaches to dosing and dose-reduction of TKI agents in the treatment of advanced RCC.
Switching a Patient with Advanced RCC Between IO + TKI and IO + IO Combination Regimens
The panel discusses which patients they would consider switching between immunotherapy combination treatments.
Approaches to the Frontline Treatment of Advanced Kidney Cancer
Experts summarize their most common frontline treatment approaches to advanced RCC.
Observing Patients with Advanced Renal Cell Carcinoma Before Systemic Therapy
Moshe Ornstein, MD, explains which patients with RCC he observes for progression prior to systemic therapy.
Impact of the CLEAR Trial Data Updates in Clinical Practice
The panel discusses the potential impact of updated data from the CLEAR trial on the treatment of patients with advanced RCC in clinical practice.
CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Additional Findings
Hans Hammers, MD, shares whether the updated CLEAR trial data would make him consider an IO-TKI regimen for patients with advanced RCC over an IO-IO regimen.
CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Updated Efficacy Outcomes
Brian Rini, MD, presents updated data from the CLEAR trial of lenvatinib plus pembrolizumab versus sunitinib in frontline advanced renal cell carcinoma.
Prostate Cancer
This management guide covers the treatment, diagnosis, and staging of prostate cancer.